Heart Rate Lowering for Coronary CTA with Ivabradine in End-Stage Liver Disease.

Rishabh Tandon Dzhalal Agakishiev Rebecca L Freese Julie Thompson Prabhjot S Nijjar

Radiol Cardiothorac Imaging

From the Department of Medicine, Cardiovascular Division, University of Minnesota Medical Center, 420 Delaware St SE, MMC 508, Minneapolis, MN 55455 (R.T., P.S.N.); Department of Medicine (D.A.) and Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition (J.T.), University of Minnesota Medical School, Minneapolis, Minn; and Clinical and Translational Science Institute, Biostatistical Design and Analysis Center, University of Minnesota, Minneapolis, Minn (R.L.F.).

Published: June 2024

In a study of 282 patients with end-stage liver disease undergoing coronary CT angiography, administration of a single dose of ivabradine (up to 15 mg) was found to be safe and effective at heart rate lowering.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11211931	PMC
http://dx.doi.org/10.1148/ryct.230402	DOI Listing

Publication Analysis

Top Keywords

heart rate

rate lowering

end-stage liver

liver disease

lowering coronary

coronary cta

cta ivabradine

ivabradine end-stage

disease study

study 282

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!